Conference Coverage

Pembrolizumab does not surpass paclitaxel for gastric cancer

Publish date: June 21, 2018

 

REPORTING FROM ESMO GI 2018

SOURCE: Shitara K. et al. ESMO World Congress on Gastrointestinal Cancer 2018. Abstract LBA-005.

Pages

Recommended Reading

Multiple solid tumors targeted by concept CAR T
MDedge Hematology and Oncology
Cemiplimab impresses in advanced CSCC
MDedge Hematology and Oncology
Checkpoint inhibitors well tolerated by NSCLC patients with preexisting autoimmune disease
MDedge Hematology and Oncology
Pembrolizumab monotherapy shows activity in advanced recurrent ovarian cancer
MDedge Hematology and Oncology
Metastatic lung cancer: Pembrolizumab plus chemo prolongs survival
MDedge Hematology and Oncology
MRD-negative status signals better outcomes in CAR T–treated ALL
MDedge Hematology and Oncology
Checkpoint inhibitor shows promise in advanced squamous-cell carcinoma
MDedge Hematology and Oncology
Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHL
MDedge Hematology and Oncology
Avelumab does not add punch to ALK inhibitors for ALK+/– NSCLC
MDedge Hematology and Oncology
Blood and tissue TMB help predict checkpoint inhibition response in NSCLC
MDedge Hematology and Oncology